MNTA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MNTA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Momenta Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Jun. 2020 was $-0.48. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2020 was $-2.12.
Momenta Pharmaceuticals's EPS (Diluted) for the three months ended in Jun. 2020 was $-0.48. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2020 was $-2.12.
Momenta Pharmaceuticals's EPS without NRI for the three months ended in Jun. 2020 was $-0.48. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2020 was -2.12.
During the past 3 years, the average EPS without NRI Growth Rate was -107.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was -16.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Momenta Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 50.80% per year. The lowest was -107.60% per year. And the median was 7.00% per year.
The historical data trend for Momenta Pharmaceuticals's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momenta Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | |||||||||||
EPS (Basic) | Get a 7-Day Free Trial | -1.32 | -0.31 | -1.20 | -2.26 | -2.92 |
Momenta Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | |
EPS (Basic) | Get a 7-Day Free Trial | -1.16 | -0.45 | -0.85 | -0.34 | -0.48 |
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Momenta Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2019 is calculated as
Basic EPS (A: Dec. 2019 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Basic Average) |
= | (-290.055 | - | 0) | / | 99.339 | |
= | -2.92 |
Momenta Pharmaceuticals's Basic EPS for the quarter that ended in Jun. 2020 is calculated as
Basic EPS (Q: Jun. 2020 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Basic Average) |
= | (-57.032 | - | 0) | / | 117.865 | |
= | -0.48 |
EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.12
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momenta Pharmaceuticals (NAS:MNTA) EPS (Basic) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Momenta Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.
Bruce Downey | director | |
Alejandra Carvajal | officer: Chief Legal Officer | C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139 |
Jose-carlos Gutierrez-ramos | director | C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142 |
Georges Gemayel | director | 550 HILLS DRIVE, BEDMINSTER NJ 07921 |
Elizabeth Stoner | director | C/O MOMENTA PHARMACEUTICALS, INC. 675 WEST KENDALL STREET CAMBRIDGE MA 02142 |
Santiago Arroyo | officer: SVP, Chief Medical Officer | C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142 |
Young Kwon | officer: Chief Financial & Bus. Officer | C/O MOMENTA PHARMACEUTICALS INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142 |
Ian Fier | officer: Chief Mfg and Program Officer | C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142 |
Steven C Gilman | director | 110 HARTWELL AVENUE, LEXINGTON MA 02421 |
Jo Ann Beltramello | officer: Chief HR and Inf. Officer | C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142 |
Jane F Barlow | director | 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487 |
Anthony M. Manning | officer: Chief Scientific Officer | C/O PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Donna Roy Grogan | director | 1133 OLD QUEEN ANNE ROAD, CHATHAM MA 02633 |
Agnieszka Cieplinska | officer: Chief Accounting Officer (PAO) | C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142 |
Craig A Wheeler | director, officer: President & CEO |
From GuruFocus
By [email protected] insider • 07-02-2020
By Marketwired Marketwired • 06-15-2020
By PRNewswire PRNewswire • 09-26-2020
By [email protected] insider • 06-18-2020
By PRNewswire PRNewswire • 08-20-2020
By Marketwired Marketwired • 08-03-2020
By PRNewswire PRNewswire • 08-19-2020
By [email protected] insider • 06-16-2020
By [email protected] insider • 03-09-2020
By Marketwired Marketwired • 12-24-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.